Once-daily tacrolimus in liver transplantation: a 'me-too drug', or a therapeutic advantage
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F17%3A00075926" target="_blank" >RIV/00023001:_____/17:00075926 - isvavai.cz</a>
Result on the web
<a href="https://insights.ovid.com/crossref?an=00075200-201704000-00005#" target="_blank" >https://insights.ovid.com/crossref?an=00075200-201704000-00005#</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/MOT.0000000000000387" target="_blank" >10.1097/MOT.0000000000000387</a>
Alternative languages
Result language
angličtina
Original language name
Once-daily tacrolimus in liver transplantation: a 'me-too drug', or a therapeutic advantage
Original language description
Purpose of review To provide latest information on differences between standard tacrolimus ( TAC BID) and slow-released formulation of tacrolimus ( Advagraf) in liver transplantation ( LTx), and to discuss the latter's therapeutic value as a distinct entity. Recent findings Two articles on de-novo studies, several on conversion and one on survival analysis from the European Liver Transplant Registry published recently showed that low-dose Advagraf immediately after transplantation provided same protection to the kidney as standard dose delayed until day 5, and was associated with lower rejection rate; to maintain the same trough level after late conversion to Advagraf, an approximately 1.25-fold higher dose was needed on average; if studied by questionnaire, conversion improved medication adherence; and registry data provided evidence of long-term survival benefit of Advagraf over TAC BID ( 7 and 8% graft and patient survival rates over a 3-year period; P<0.002 and P<0.003, respectively). Summary Pharmacokinetic differences between TAC BID and Advagraf translate into less interpatient and intrapatient variability and improve adherence. If survival benefit of Advagraf administration de novo after LTx as demonstrated by the European Liver Transplant Registry analysis is confirmed in an independent cohort, Advagraf will leave the area of the 'me-too' drugs to become the immunosuppressant of choice.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30213 - Transplantation
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Current opinion in organ transplantation
ISSN
1087-2418
e-ISSN
—
Volume of the periodical
22
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
5
Pages from-to
118-122
UT code for WoS article
000396215900004
EID of the result in the Scopus database
—